Drew Moss

Pembrolizumab and Olaparib Maintenance in Pancreatic Cancer: Interpreting the POLAR Data @GiOncNow #PrecisionImmunotherapy #POLAR @MSK_DeptOfMed @PICIatMSK @MSKCancerCenter @EileenMOReilly nature.com/articles/s4159… 📽️ Summary: gioncologynow.com/post/pembroliz…

The crowd surrounding this @EileenMOReilly late breaking poster is going to be huge! Also today afternoon. #AACR26

Landscape of #PancreaticCancer treatment is changing! @EileenMOReilly, a gastrointestinal medical oncologist @MSK_DeptOfMedwho was involved with the studies on daraxonrasib, says the encouraging findings about daraxonrasib "hopefully set the stage for building on targeted therapy as a major backbone for the treatment of pancreas cancer, and a key goal now is to build and extend these results in all stages." “I’ve already told my colleagues that today is an inflection point that if things stays positive, everything should change,” says Dr. Wungki Park @CentralParkWMD, a pancreatic cancer specialist @MSKCancerCenter, who was involved in the early human trials of daraxonrasib. “There will be pre-daraxonrasib and post-daraxonrasib. This is a really, really good outcome.” Congratulations to Elraglusib team! nature.com/articles/s4159… Devalingam Mahalingam,@rachnatshroffBenedito Carneiro and@GIcancerDoc time.com/article/2026/0…

GO. BLUE. 🏆 MICHIGAN IS THE FIRST BIG TEN TEAM TO WIN A NATIONAL CHAMPIONSHIP SINCE 2000! 🔥

A new drug is showing promise in lung and pancreatic cancers (two of the most aggressive forms of cancer) by targeting one of the most common cancer-driving mutations. Researchers at Memorial Sloan Kettering Cancer Center (MSK), including gastrointestinal medical oncologist @CentralParkWMD who led the global phase 1 clinical trial, shared results published in the @NEJM. The trial tested setidegrasib, a drug that tags and destroys the cancer-causing protein produced by the KRAS G12D mutation. This new method for targeting a long-known mutation is called a KRAS degrader. KRAS mutations are present in about 1 in 5 cancers. The G12D subtype drives about 40% of pancreatic cancers and 5% of non-small cell lung cancers. “This drug’s potential is exciting,” says Dr. Park, “because the trial results suggest that setidegrasib can not only extend life for some patients with these aggressive cancers, it also has a very good safety profile, meaning the drug was well-tolerated with side effects that can be managed quite easily." Learn more about this research: bit.ly/4lSeoJa

It's hard to believe I started working on POLAR my first year of college, and now I am finishing my first clinical rotation on Friday. Endlessly grateful for everything I learned over the past 5 years from @CentralParkWMD, @EileenMOReilly & all the patients who were part of POLAR

🤯🤯 Huge congratulations to @CentralParkWMD for two first-author papers in NEJM and Nature Medicine - on the same day! Truly extraordinary contribution to the field. Proud to be part of this @MSKCancerCenter team! @EileenMOReilly @ciacobu

I learned so much writing this review of novel PDAC therapies with my brilliant mentors @EileenMOReilly & @CentralParkWMD. Amazing to have multiple targeted therapies with single agent activity. It's a great time to start a career in PDAC drug development. link.springer.com/article/10.100…

Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

It's all ours. 🏆 The Michigan Wolverines are the 𝙊𝙐𝙏𝙍𝙄𝙂𝙃𝙏 champions of the Big Ten.

Are two #PancreaticCancers in the organ independent lesions or clonally related. Work by @EileenMOReilly & colleagues suggests that most are related lesions because of intra-pancreatic spread. These often have indolent biological features (KRAS SMAD4 WT). nature.com/articles/s4169…

K/RAS mutation is 95% present in #PDAC new treatments are coming 🌊 Great to connect and meet experts in GI cancer! @rutikamehtaMD @aparna1024

This isn’t a random scientist who got lucky. Mariano Barbacid discovered the first human oncogene in 1982. He isolated H-RAS from bladder cancer cells and proved a single point mutation could trigger cancer. That finding launched the entire field of molecular oncology. KRAS mutations cause 90% of pancreatic cancers. For 43 years, oncologists called KRAS “undruggable” because the protein had no obvious binding pocket. Barbacid spent the last decade using genetically engineered mice to systematically test every node in the KRAS signaling pathway, looking for combinations that would work without killing the patient. The triple therapy blocks KRAS three ways at once: the main growth signal, the escape routes through EGFR and HER2, and the stress-response backup through STAT3. Cut the engine, seal the exits, disable the emergency system. Tumors vanished in mice and didn’t return for 200+ days after treatment stopped. Pancreatic cancer has a 13% five-year survival rate. 8% for the ductal adenocarcinoma type this therapy targets. Most patients live one year after diagnosis. The catch: this is preclinical. Human trials are 3+ years away. One of the drugs, RMC-6236, might get approved this year, but the full triple combination has regulatory hurdles. Still. The man who discovered human oncogenes in 1982 may have just figured out how to eliminate the cancer those genes cause. That’s a 43-year arc from first principles to potential cure. Science rarely works this clean.

These are two of the most talented stars that I have had the privilege to work alongside - @CentralParkWMD @JonathanLee23 - pancreas cancer - stay tuned!

New Targeted Therapies Show Early Promise in #KRASG12D #PancreaticCancer @ASCO #GI26 Congrats 🎉 Wainberg INCB-734 • 1200 mg mono: ORR 37% • 1L GemNabP combo: ORR 4/8 @anup_kasi Setidegrasib • 2L/3L mono: ORR 24% • 1L mFOLFIRINOX combo: ORR 7/12 dailynews.ascopubs.org/do/new-targete…

𝐎𝐟𝐟𝐢𝐜𝐢𝐚𝐥: Welcome to Michigan, Coach Whittingham! 〽️ 🗞️ myumi.ch/w9PJN

Former Utah coach Kyle Whittingham has agreed to a five-year deal to become Michigan’s next head coach, sources tell @PeteThamel and @DanWetzel.

Love❤️ gratitude🙇🏻 & best wishes🙏🏼from our #PancreaticCancer team @MSKCancerCenter Wishing you and your loved ones happy holidays and a hopeful New Year. 🥂Here’s to progress, purpose and taking care of one another. #TeamScience #HumansBeyondPatients @CpcrMsk @MSK_DeptOfMed

Celebrating another amazing year with current and incoming fellows at our holiday party @Perlmutter_CC @NYULISOM_HemOnc

@CarlMcJenkins Happy Birthday to a Michigan and Detroit legend!

I’m the Birthday Bitch today 💁🏻‍♀️ 🎊🎉🍾